Table 1.
References | Country | Setting | Studied area | Study type |
Sample size
(intervention vs. control) |
Patient characteristics | Intervention | Control | Duration (months) | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Age * (year) | Male (%) | NAFLD diagnosis method | DM (%) | |||||||||
Fard et al. (18) | Iran | Single school of Nursing and Midwifery | Urban | RCT | 30 vs. 30 | Intervention 40.3 Control 38.3 |
76.3% | Ultrasound | 0% | Telephone | Usual care | 3 |
Axley et al. (19) | USA | Department of Internal Medicine, University of Texas Medical | Urban | RCT | 13 vs. 17 | Intervention 54 ± 2.7 Control 52 ± 2.3 |
33% | Ultrasound, elevate liver enzyme | Intervention 38% Control 30% |
Text messaging | Usual care | 6 |
Vilar-Gomez et al. (20) | USA | 4 Universities | NA | Non-RCT | 157 vs. 38 | Intervention 53.8 ± 8.4 Control 52.3 ± 9.5 |
37% | Non-invasive scores | 100% | On-site education classes or via web-based | Usual care | 12 |
Mazzotti et al. (17) | Italy | Unit of Metabolic Diseases and Clinical Dietetics, University of Bologna |
Urban and rural | Non-RCT | 278 vs. 438 | Intervention web-treated 46.0 ± 11.5 Intervention group-treated 55.1 ± 12.3 |
53.5% | Ultrasound | Intervention web-treated 21.6% Intervention group-treated 40.6% |
Web-based program | Group-base program | 24 |
DM, diabetes mellitus; NA, not available; NAFLD, non-alcoholic fatty liver disease; RCT, randomized controlled trial; USA, United States of America.
Values are presented as mean ± standard deviation.